Warning: The NCBI web site requires JavaScript to function. more...
Active synovial matrix metalloproteinase-2 is associated with radiographic erosions in patients with early synovitis.
Goldbach-Mansky R, Lee JM, Hoxworth JM, Smith D 2nd, Duray P, Schumacher RH Jr, Yarboro CH, Klippel J, Kleiner D, El-Gabalawy HS.
Arthritis Res. 2000;2(2):145-53. Epub 2000 Feb 9.
Related citations
Gelatinase expression and activity in the synovium and skin of patients with erosive psoriatic arthritis.
Hitchon CA, Danning CL, Illei GG, El-Gabalawy HS, Boumpas DT.
J Rheumatol. 2002 Jan;29(1):107-17.
Early joint erosions and serum levels of matrix metalloproteinase 1, matrix metalloproteinase 3, and tissue inhibitor of metalloproteinases 1 in rheumatoid arthritis.
Cunnane G, Fitzgerald O, Beeton C, Cawston TE, Bresnihan B.
Arthritis Rheum. 2001 Oct;44(10):2263-74.
Synovial tissue protease gene expression and joint erosions in early rheumatoid arthritis.
Cunnane G, FitzGerald O, Hummel KM, Youssef PP, Gay RE, Gay S, Bresnihan B.
Arthritis Rheum. 2001 Aug;44(8):1744-53.
Involvement of matrix metalloproteinases and their inhibitors in peripheral synovitis and down-regulation by tumor necrosis factor alpha blockade in spondylarthropathy.
Vandooren B, Kruithof E, Yu DT, Rihl M, Gu J, De Rycke L, Van Den Bosch F, Veys EM, De Keyser F, Baeten D.
Arthritis Rheum. 2004 Sep;50(9):2942-53.
Expression of matrix metalloproteinase 9 (96-kd gelatinase B) in human rheumatoid arthritis.
Ahrens D, Koch AE, Pope RM, Stein-Picarella M, Niedbala MJ.
Arthritis Rheum. 1996 Sep;39(9):1576-87.
Serum matrix metalloproteinases and tissue inhibitors of metalloproteinases in different histological variants of rheumatoid synovitis.
Klimiuk PA, Sierakowski S, Latosiewicz R, Cylwik B, Skowronski J, Chwiecko J.
Rheumatology (Oxford). 2002 Jan;41(1):78-87.
Examination of in vivo gelatinolytic activity in rheumatoid arthritis synovial tissue using newly developed in situ zymography and image analyzer.
Yoshida W, Uzuki M, Nishida J, Shimamura T, Sawai T.
Clin Exp Rheumatol. 2009 Jul-Aug;27(4):587-93.
Circulating levels of matrix metalloproteinases MMP-3 and MMP-1, tissue inhibitor of metalloproteinases 1 (TIMP-1), and MMP-1/TIMP-1 complex in rheumatic disease. Correlation with clinical activity of rheumatoid arthritis versus other surrogate markers.
Keyszer G, Lambiri I, Nagel R, Keysser C, Keysser M, Gromnica-Ihle E, Franz J, Burmester GR, Jung K.
J Rheumatol. 1999 Feb;26(2):251-8.
Reduced chemokine and matrix metalloproteinase expression in patients with rheumatoid arthritis achieving remission.
Katrib A, Smith MD, Ahern MJ, Slavotinek J, Stafford L, Cuello C, Bertouch JV, McNeil HP, Youssef PP.
J Rheumatol. 2003 Jan;30(1):10-21.
Quantitation of metalloproteinase gene expression in rheumatoid and psoriatic arthritis synovial tissue distal and proximal to the cartilage-pannus junction.
Kane D, Jensen LE, Grehan S, Whitehead AS, Bresnihan B, Fitzgerald O.
J Rheumatol. 2004 Jul;31(7):1274-80.
MMP-2, MMP-9, TIMP-1 and TIMP-2 levels in patients with rheumatoid arthritis and psoriatic arthritis.
Giannelli G, Erriquez R, Iannone F, Marinosci F, Lapadula G, Antonaci S.
Clin Exp Rheumatol. 2004 May-Jun;22(3):335-8.
Turnover of type II collagen and aggrecan in cartilage matrix at the onset of inflammatory arthritis in humans: relationship to mediators of systemic and local inflammation.
Fraser A, Fearon U, Billinghurst RC, Ionescu M, Reece R, Barwick T, Emery P, Poole AR, Veale DJ.
Arthritis Rheum. 2003 Nov;48(11):3085-95.
Matrix metalloproteinases and tissue inhibitors of metalloproteinases in synovial fluids from patients with rheumatoid arthritis or osteoarthritis.
Yoshihara Y, Nakamura H, Obata K, Yamada H, Hayakawa T, Fujikawa K, Okada Y.
Ann Rheum Dis. 2000 Jun;59(6):455-61.
Activation of synovial fibroblasts in rheumatoid arthritis: lack of Expression of the tumour suppressor PTEN at sites of invasive growth and destruction.
Pap T, Franz JK, Hummel KM, Jeisy E, Gay R, Gay S.
Arthritis Res. 2000;2(1):59-64.
Anti-tumour necrosis factor (TNF)-alpha therapy (etanercept) down-regulates serum matrix metalloproteinase (MMP)-3 and MMP-1 in rheumatoid arthritis.
Catrina AI, Lampa J, Ernestam S, af Klint E, Bratt J, Klareskog L, Ulfgren AK.
Rheumatology (Oxford). 2002 May;41(5):484-9.
Analysis of the cell infiltrate and expression of proinflammatory cytokines and matrix metalloproteinases in arthroscopic synovial biopsies: comparison with synovial samples from patients with end stage, destructive rheumatoid arthritis.
Smeets TJ, Barg EC, Kraan MC, Smith MD, Breedveld FC, Tak PP.
Ann Rheum Dis. 2003 Jul;62(7):635-8.
Presence of active gelatinases in endometrial carcinoma and correlation of matrix metalloproteinase expression with increasing tumor grade and invasion.
Di Nezza LA, Misajon A, Zhang J, Jobling T, Quinn MA, Ostör AG, Nie G, Lopata A, Salamonsen LA.
Cancer. 2002 Mar 1;94(5):1466-75.
New collagenolytic enzymes/cascade identified at the pannus-hard tissue junction in rheumatoid arthritis: destruction from above.
Konttinen YT, Ceponis A, Takagi M, Ainola M, Sorsa T, Sutinen M, Salo T, Ma J, Santavirta S, Seiki M.
Matrix Biol. 1998 Dec;17(8-9):585-601.
Expression and activation of matrix metalloproteinase-2 (MMP-2) and its co-localization with membrane-type 1 matrix metalloproteinase (MT1-MMP) correlate with melanoma progression.
Hofmann UB, Westphal JR, Zendman AJ, Becker JC, Ruiter DJ, van Muijen GN.
J Pathol. 2000 Jul;191(3):245-56.
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on